MaryAnne Visit 1: A middle-aged woman going through a troublesome divorce
| Title: | MaryAnne Visit 1: A middle-aged woman going through a troublesome divorce |
| Topic: | Psychiatry |
| Relevant Terms: | Fibromyalgia, Mood Disorders, Pain Management |
| Primary Audience: | Psychiatrists |
| Launch Date: | 22-Feb-10 |
| Credits: | 1 AMA PRA Category 1 Credit™ |
| Expiration Date: | 21-Feb-11 |
Learning Objectives
Upon completion of the activity, participants should be able to:
- Utilize a combination of ACR criteria, physical examination, and patient history in the diagnosis of fibromyalgia.
- Describe two central nervous system pathways, which may contribute to the pathophysiology of fibromyalgia.
- Review the current evidence-based recommendations for the treatment of fibromyalgia.
- Implement evidence-based use of treatment regimens in patients with fibromyalgia.
Faculty
Lesley M. Arnold, MD
Professor of Psychiatry
Director, Women's Health Research Program
University of Cincinnati College of Medicine
Cincinnati, Ohio
Michael R. Clark, MD, MPH
Associate Professor & Director
Chronic Pain Treatment Programs
Department of Psychiatry & Behavioral Sciences
The Johns Hopkins Medical Institutions
Baltimore, Maryland
Daniel J. Clauw, MD
Professor of Medicine
Division of Rheumatology
Associate Dean for Clinical and Translational Research
Director, Chronic Pain and Fatigue Research Center
Michigan Institute for Clinical and Health Research
University of Michigan
Ann Arbor, Michigan
Chaim Putterman, MD; Course Director/Reviewer
Guest Faculty
Professor, Departments of Medicine (Rheumatology), Microbiology and Immunology
Chief, Division of Rheumatology
Albert Einstein College of Medicine
Bronx, New York
Professor of Psychiatry
Director, Women's Health Research Program
University of Cincinnati College of Medicine
Cincinnati, Ohio
Michael R. Clark, MD, MPHAssociate Professor & Director
Chronic Pain Treatment Programs
Department of Psychiatry & Behavioral Sciences
The Johns Hopkins Medical Institutions
Baltimore, Maryland
Daniel J. Clauw, MDProfessor of Medicine
Division of Rheumatology
Associate Dean for Clinical and Translational Research
Director, Chronic Pain and Fatigue Research Center
Michigan Institute for Clinical and Health Research
University of Michigan
Ann Arbor, Michigan
Chaim Putterman, MD; Course Director/ReviewerGuest Faculty
Professor, Departments of Medicine (Rheumatology), Microbiology and Immunology
Chief, Division of Rheumatology
Albert Einstein College of Medicine
Bronx, New York
COURSE VIEWING REQUIREMENTS
ESTIMATED TIME TO COMPLETE THIS ACTIVITY: 1.00 hour
| PC
Internet Explorer (v6 or greater), or Firefox
|
MAC Safari |
ESTIMATED TIME TO COMPLETE THIS ACTIVITY: 1.00 hour
SPONSOR
This activity is sponsored by Albert Einstein College of Medicine in collaboration with SciMed and RealCME.
INTENDED AUDIENCE: Psychiatrists interested in learning more about the management of their patients with fibromyalgia.
STATEMENT OF NEED
Despite increasing incidence and public awareness, recognition of fibromyalgia by psychiatrists can be poor. Psychiatrists inherently fail to identify and appreciate the cumulative symptoms of fibromyalgia, resulting in significant delays in diagnosis and treatment, as well as diminished patient quality of life.
Contrary to the most recent data on the pathophysiology of fibromyalgia, many psychiatrists continue to believe that fibromyalgia is a somatoform disorder. Due to the rapid increase in understanding of fibromyalgia pathophysiology, many psychiatrists are often unaware that fibromyalgia has a defined neurological etiology that is quantifiable, which may delay diagnosis, and result in inappropriate treatment and poor health outcomes.
Psychiatrists fail to adhere to fibromyalgia evidence-based treatment regimens, and are not informed of innovative therapies indicated for the treatment of fibromyalgia. Poor understanding and implementation of the latest advancements in fibromyalgia treatment regimens may lead to patients with unmanaged pain and fatigue, resulting in diminished patient quality of life and poor health outcomes.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Albert Einstein College of Medicine and SciMed. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Albert Einstein College of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
DISCLOSURE STATEMENT
Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
Albert Einstein College of Medicine CCME Staff, and the staff of RealCME have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Shari Fallet, D.O., employed by SciMed and a member of the planning committee, has disclosed that she owns stock with Pfizer.
FACULTY DISCLOSURES
FACULTY DISCLOSURES
Lesley M. Arnold, MD: Allergan, Boehringer Ingelheim, Cypress Biosciences Inc, Eli Lilly and Company, Forest Laboratories, Pfizer Inc, Wyeth (Grants/Research); Allergan, AstraZeneca, Boehringer Ingelheim, Cypress Biosciences Inc, Eli Lilly and Company, Forest Laboratories, Pfizer Inc, sanofi-aventis, Takeda Pharmaceuticals, Theravance, UCB Pharma, Wyeth (Consultant); Forest Laboratories, Eli Lilly and Company, Pfizer Inc (Speakers Bureau).
Michael R. Clark, MD: Eli Lilly and Company (Consultant); Eli Lilly and Company (Speaker's Bureau).
Daniel J. Clauw, MD: Forest Laboratories, Pfizer Inc (Grants/Research); AstraZeneca, Cypress Biosciences Inc, Eli Lilly and Company, Forest Laboratories, Pfizer Inc, Pierre Fabre USA, UCB Pharma, Wyeth (Consultant).
Chaim Putterman, MD: Biogen Idec (Grants/Research); Rosetta Genomics (Consultant).
OFF-LABEL PRODUCT DISCUSSION
Faculty have indicated that this activity will include the following off-label discussions: a) Use of pregabalin for sleep; b) slower dose titration for pregabalin; c) use of fluoxetine in a fibromyalgia patient; d) use of the broad terms "SNRI" and "alpha 2 delta ligand" for treatment of fibromyalgia; e)use of non-pharmacological treatments for fibromyalgia including exercise, CBT, and education; f) use of NSAIDs in fibromyalgia patients
METHOD OF PARTICIPATION AND RECEIVING CME/CE CREDIT
There are no fees for participating in and receiving credit for this activity. The participant must read the objectives and enduring material and must answer the multiple-choice online post-test. Please complete the evaluation form, which provides each participant with the opportunity to comment on the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and his/her views on future educational needs. A score of at least 70% is required to successfully complete this activity. The participant may take the test until successfully passed. Credit is available through February, 2011.
DISCLAIMER
The opinions and recommendations expressed by faculty in this activity are their own and do not necessarily represent the views of Albert Einstein College of Medicine, Montefiore Medical Center, and SciMed. Please review complete prescribing information for specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
COPYRIGHT INFORMATION
Copyright © 2010 Albert Einstein College of Medicine. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.
PRIVACY POLICY
Albert Einstein College of Medicine, Center for Continuing Medical Education (Einstein) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
Einstein maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.
Additional information regarding Albert Einstein College of Medicine's Privacy Policy can be viewed at http://www.mecme.org/site/privacy.php.
If you have questions about this CME activity, please contact Albert Einstein College of Medicine at 1-718-920-6674 or cme@montefiore.org.
ACKNOWLEDGEMENT
This activity is supported by an educational grant from Pfizer.
Michael R. Clark, MD: Eli Lilly and Company (Consultant); Eli Lilly and Company (Speaker's Bureau).
Daniel J. Clauw, MD: Forest Laboratories, Pfizer Inc (Grants/Research); AstraZeneca, Cypress Biosciences Inc, Eli Lilly and Company, Forest Laboratories, Pfizer Inc, Pierre Fabre USA, UCB Pharma, Wyeth (Consultant).
Chaim Putterman, MD: Biogen Idec (Grants/Research); Rosetta Genomics (Consultant).
OFF-LABEL PRODUCT DISCUSSION
Faculty have indicated that this activity will include the following off-label discussions: a) Use of pregabalin for sleep; b) slower dose titration for pregabalin; c) use of fluoxetine in a fibromyalgia patient; d) use of the broad terms "SNRI" and "alpha 2 delta ligand" for treatment of fibromyalgia; e)use of non-pharmacological treatments for fibromyalgia including exercise, CBT, and education; f) use of NSAIDs in fibromyalgia patients
METHOD OF PARTICIPATION AND RECEIVING CME/CE CREDIT
There are no fees for participating in and receiving credit for this activity. The participant must read the objectives and enduring material and must answer the multiple-choice online post-test. Please complete the evaluation form, which provides each participant with the opportunity to comment on the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and his/her views on future educational needs. A score of at least 70% is required to successfully complete this activity. The participant may take the test until successfully passed. Credit is available through February, 2011.
DISCLAIMER
The opinions and recommendations expressed by faculty in this activity are their own and do not necessarily represent the views of Albert Einstein College of Medicine, Montefiore Medical Center, and SciMed. Please review complete prescribing information for specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
COPYRIGHT INFORMATION
Copyright © 2010 Albert Einstein College of Medicine. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.
PRIVACY POLICY
Albert Einstein College of Medicine, Center for Continuing Medical Education (Einstein) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
Einstein maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.
Additional information regarding Albert Einstein College of Medicine's Privacy Policy can be viewed at http://www.mecme.org/site/privacy.php.
If you have questions about this CME activity, please contact Albert Einstein College of Medicine at 1-718-920-6674 or cme@montefiore.org.
RELEASE DATE: February 22, 2010
TERMINATION DATE: February 21, 2011
TERMINATION DATE: February 21, 2011
ACKNOWLEDGEMENT
This activity is supported by an educational grant from Pfizer.
